Case Study – France

  • Elisande NexonEmail author
Conference paper
Part of the NATO Science for Peace and Security Series A: Chemistry and Biology book series (NAPSA)


Emerging health risks, weapons of mass destruction, and terrorism – including biological weapons and bioterrorism – are identified in the 2008 White Paper on defence and national security as threats for France and its citizens. Since the beginning of the century, the 2001 anthrax attacks in the USA and subsequent hoaxes as well as the global SARS outbreak and influenza pandemic threats have all contributed to raise public awareness about health emergencies, leading authorities to adapt and improve planning for such events. This chapter focuses on natural and intentional public health threats and on biopreparedness from a French perspective, describing legal and organizational frameworks, plans and guidelines.


Crisis Management Syndromic Surveillance Public Health Threat National Territory Security Area 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Buehler J, Hopkins R, Overhage J, Sosin D, Tong V (2004) Framework for evaluating public health surveillance systems for early detection of outbreaks. MMWR 50(13):1–35Google Scholar
  2. 2.
    French National Ethics Committee for Health and Life Science (2009), Opinion n°106: Ethical issues raised by a possible influenza pandemicGoogle Scholar
  3. 3.
    Josseran L, Fouillet A, Caillère N, Brun-Ney D, Ilef D, Brucker G, Mediros H, Astagneau P (2010) Assessment of a syndromic surveillance system based on morbidity data: results from the Oscour network during heat wave. PLoS One 5(8):e11984PubMedCrossRefGoogle Scholar
  4. 4.
    Institut de Veille Sanitaire (2011), Rapport Annuel 2010. Institut de Veille Sanitaire, Saint-Maurice, p 7Google Scholar
  5. 5.
    Mailles A, Alauzet C, Mock M, Garin-Bastuji B, Veran Y (2010) Cas groupés de charbon cutané humain en Moselle – Décembre 2008. Institut de Veille Sanitaire, Saint-MauriceGoogle Scholar
  6. 6.
    Mazuet C, Bouvet P, King LA, Popoff M (2011) Le botulisme humain en France, 2007–2009. BEH 6:49–53Google Scholar
  7. 7.
    Stoto M, Schonlau M, Mariano L (2004) Syndromic surveillance: is it worth the effort? Chance 17(1):19–24Google Scholar
  8. 8.
    Taylor T (2006) Safeguarding advances in the life sciences: The International Council for the Life Sciences is committed to becoming the authoritative source for identifying and managing biological risks. EMBO Rep 7:S61–S64PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Fondation pour la recherche stratégiqueParisFrance

Personalised recommendations